Artelo Biosciences, Inc. (NASDAQ:ARTL) Given Average Rating of “Hold” by Brokerages

Shares of Artelo Biosciences, Inc. (NASDAQ:ARTL) have received an average recommendation of “Hold” from the five ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $24.00.

ARTL has been the topic of several research analyst reports. Maxim Group reissued a “hold” rating on shares of Artelo Biosciences in a research report on Wednesday, November 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Artelo Biosciences in a research note on Monday, December 29th.

Artelo Biosciences Trading Up 1.8%

Artelo Biosciences stock opened at $1.71 on Friday. The company has a fifty day simple moving average of $1.64 and a 200-day simple moving average of $4.95. The stock has a market cap of $3.45 million, a P/E ratio of -0.08 and a beta of 1.04. Artelo Biosciences has a 12-month low of $1.15 and a 12-month high of $28.60.

Artelo Biosciences (NASDAQ:ARTL) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($3.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($3.15). As a group, sell-side analysts forecast that Artelo Biosciences will post -2.62 earnings per share for the current fiscal year.

About Artelo Biosciences

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.